Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice

Vaccine

Volumn 28, Issue 18, 2010, Pages 3192-3200

  Zou, Yu ^a   Sonderegger, Ivo ^b   Lipowsky, Gerd ^a   Jennings, Gary T ^a   Schmitz, Nicole ^a   Landi, Marco ^a   Kopf, Manfred ^b   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Asthma; Eosinophilia; Eotaxin; Interleukun 5; Virus like particle

Indexed keywords

EOTAXIN; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; VIRUS LIKE AGENT;

ALLERGENS; ALLOLEVIVIRUS; ANIMALS; AUTOANTIBODIES; CHEMOKINE CCL11; EOSINOPHILIA; FEMALE; HYPERSENSITIVITY; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; OVALBUMIN; RESPIRATORY TRACT DISEASES; VACCINATION; VACCINES, VIROSOME; VIRAL PROTEINS;

EID: 77949914164     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.048     Document Type: Article

References (50)

1. Bousquet J., Chanez P., Lacoste J.Y., Barneon G., Ghavanian N., Enander I., et al. Eosinophilic inflammation in asthma. The New England Journal of Medicine 323 October (15) (1990) 1033-1039
2. Rothenberg M.E., and Hogan S.P. The eosinophil. Annual Review of Immunology 24 (2006) 147-174
3. Bandeira-Melo C., Bozza P.T., and Weller P.F. The cellular biology of eosinophil eicosanoid formation and function. The Journal of Allergy and Clinical Immunology 109 March (3) (2002) 393-400
4. Lopez A.F., Begley C.G., Williamson D.J., Warren D.J., Vadas M.A., and Sanderson C.J. Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. The Journal of Experimental Medicine 163 May (5) (1986) 1085-1099
5. Rothenberg M.E., Pomerantz J.L., Owen Jr. W.F., Avraham S., Soberman R.J., Austen K.F., et al. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. The Journal of Biological Chemistry 263 September (27) (1988) 13901-13908
6. Takatsu K. Interleukin-5: an overview. Cancer Treatment and Research 80 (1995) 187-208
7. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 June (12) (1992) 3101-3109
8. Collins P.D., Marleau S., Griffiths-Johnson D.A., Jose P.J., and Williams T.J. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. The Journal of Experimental Medicine 182 October (4) (1995) 1169-1174
9. Mattes J., Yang M., Mahalingam S., Kuehr J., Webb D.C., Simson L., et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. The Journal of Experimental Medicine 195 June (11) (2002) 1433-1444
10. Foster P.S., Hogan S.P., Yang M., Mattes J., Young I.G., Matthaei K.I., et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends in Molecular Medicine 8 April (4) (2002) 162-167
11. Weltman J.K., and Karim A.S. IL-5: biology and potential therapeutic applications. Expert Opinion on Investigational Drugs 9 March (3) (2000) 491-496
12. Palframan R.T., Collins P.D., Williams T.J., and Rankin S.M. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91 April (7) (1998) 2240-2248
13. Shinkai A., Yoshisue H., Koike M., Shoji E., Nakagawa S., Saito A., et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. Journal of Immunology 163 August (3) (1999) 1602-1610
14. Zimmermann N., Hogan S.P., Mishra A., Brandt E.B., Bodette T.R., Pope S.M., et al. Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. Journal of Immunology 165 November (10) (2000) 5839-5846
15. Eum S.Y., Maghni K., Hamid Q., Eidelman D.H., Campbell H., Isogai S., et al. Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13. The Journal of Allergy and Clinical Immunology 111 May (5) (2003) 1049-1061
16. Tanaka H., Komai M., Nagao K., Ishizaki M., Kajiwara D., Takutsu K., et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. American Journal of Respiratory Cell and Molecular Biology 31 July (2004) 62-68
17. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. The Journal of Clinical Investigation 112 October (7) (2003) 1029-1036
18. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monterio W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine 360 March (2009) 973-984
19. Nair P., Pizzichini M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New England Journal of Medicine 360 March (2009) 985-993
20. Aarden L., Ruuls S.R., and Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Current Opinion in Immunology 20 August (4) (2008) 431-435
21. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science (New York, NY) 262 November (5138) (1993) 1448-1451
22. Chackerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. Journal of Immunology 169 December (11) (2002) 6120-6126
23. Chackerian B., Lowy D.R., and Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. The Journal of Clinical Investigation 108 August (3) (2001) 415-423
24. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 August (25-26) (2002) 3104-3112
25. Spohn G., Schwarz K., Maurer P., Illges H., Rajasekaran N., Choi Y., et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. Journal of Immunology 175 November (9) (2005) 6211-6218
26. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371 March (9615) (2008) 821-827
27. O'Garra A., Barbis D., Wu J., Hodgkin P.D., Abrams J., and Howard M. The BCL1 B lymphoma responds to IL-4, IL-5, and GM-CSF. Cellular Immunology 123 October (1) (1989) 189-200
28. Cielens I., Ose V., Petrovskis I., Strelnikova A., Renhofa R., Kozlovska T., et al. Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods. FEBS Letters 482 October (3) (2000) 261-264
29. Lendrum A.C. The staining of eosinophil polymorphs and enterochromaffin cells in histological sections. Journal of Pathology & Bacteriology 56 (1944) 441-442
30. Das A.M., Flower R.J., and Perretti M. Eotaxin-induced eosinophil migration in the peritoneal cavity of ovalbumin-sensitized mice: mechanism of action. Journal of Immunology 159 August (3) (1997) 1466-1473
31. Clark M. Antibody humanization: a case of the emperor's new clothes. Immunology Today 21 August (8) (2000) 397-402
32. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. Journal of Pharmaceutical Sciences 92 August (8) (2003) 1665-1676
33. Hwang W.Y., and Foote J. Immunogenicity of engineered antibodies. Methods 36 May (1) (2005) 3-10
34. Bachmann M.F., and Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nature Reviews 3 January (1) (2004) 81-88
35. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. Journal of Immunology 167 October (7) (2001) 3792-3799
36. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. European Journal of Immunology 36 November (11) (2006) 2857-2867
37. Kundig T.M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B.M., Fulurija A., et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. The Journal of Allergy and Clinical Immunology 117 June (6) (2006) 1470-1476
38. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. Journal of Hypertension 25 January (1) (2007) 63-72
39. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. European Journal of Immunology 35 July (7) (2005) 2031-2040
40. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3 6 (2008) e2547
41. Boyce J.A., and Austen K.F. No audible wheezing: nuggets and conundrums from mouse asthma models. The Journal of Experimental Medicine 201 June (12) (2005) 1869-1873
42. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., and Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. The Journal of Experimental Medicine 183 January (1) (1996) 195-201
43. Hamelmann E., Cieslewicz G., Schwarze J., Ishizuka T., Joetham A., Heusser C., et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine 160 September (3) (1999) 934-941
44. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. American Journal of Respiratory and Critical Care Medicine 167 June (12) (2003) 1655-1659
45. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 December (9248) (2000) 2144-2148
46. Jarman E.R., and Lamb J.R. Reversal of established CD4+ type 2 T helper-mediated allergic airway inflammation and eosinophilia by therapeutic treatment with DNA vaccines limits progression towards chronic inflammation and remodelling. Immunology 112 August (4) (2004) 631-642
47. Kay A.B., Phipps S., and Robinson D.S. A role for eosinophils in airway remodelling in asthma. Trends in Immunology 25 September (9) (2004) 477-482
48. Trifilieff A., Fujitani Y., Coyle A.J., Kopf M., and Bertrand C. IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation. Clinical and Experimental Allergy 31 June (6) (2001) 934-942
49. Mathur M., Herrmann K., Li X., Qin Y., Weinstock J., et al. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. American Journal of Respiratory and Critical Care Medicine 159 February (2) (1999) 580-587
50. Mauser P.J., Pitman A., Witt A., Fernadez X., Zurcher J., et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. American Review of Respiratory Disease 148 December (6 Pt (1)) (1993) 1623-1627